Niagen Bioscience, Inc. (NAGE) — 10-Q Filings

10-Q Filings (6)

• Niagen Bioscience Q3 Sales Soar 33%, Net Income Jumps 144% — Nov 4, 2025 Risk: medium
  Niagen Bioscience, Inc. (NAGE) reported robust financial performance for the three and nine months ended September 30, 2025. Net sales increased significantly,
• Niagen Bioscience 10-Q Lacks Key Financials, Equity Stagnant — Aug 6, 2025 Risk: high
  Niagen Bioscience, Inc. (NAGE) filed its 10-Q on August 6, 2025, for the period ending June 30, 2025. The filing indicates no specific revenue or net income fig
• Niagen Bioscience Files Q1 2025 10-Q — May 7, 2025 Risk: low
  Niagen Bioscience, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as ChromaDex Corp., is in the medicinal chemicals and b
• ChromaDex Settles with Dartmouth, Waives $3.5M in Fees — Oct 31, 2024 Risk: medium
  ChromaDex Corp. reported on its 10-Q filing for the period ending September 30, 2024. A significant subsequent event is the Settlement Agreement with Dartmouth
• ChromaDex Corp. Files Q2 2024 10-Q — Aug 7, 2024 Risk: medium
  ChromaDex Corp. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance. The company's fiscal year ends on December 31st. Key
• ChromaDex Corp. Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk: medium
  ChromaDex Corp. (NAGE) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. ChromaDex Corp. filed a 10-Q report for the period ending March 31, 2024. Th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX